Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Down 68.5% in May

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totaling 6,757 shares, a decrease of 68.5% from the April 30th total of 21,481 shares. Based on an average daily volume of 32,441 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.7% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Bluejay Diagnostics Trading Down 1.8%

Shares of BJDX traded down $0.04 during trading hours on Friday, reaching $2.14. 108,146 shares of the company’s stock traded hands, compared to its average volume of 69,387. Bluejay Diagnostics has a 12 month low of $1.62 and a 12 month high of $16.68. The stock has a market cap of $2.20 million, a PE ratio of -0.18 and a beta of 0.72. The firm’s 50 day simple moving average is $1.90 and its 200-day simple moving average is $2.87.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC bought a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics as of its most recent SEC filing. Hedge funds and other institutional investors own 18.47% of the company’s stock.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.